Plain-English translation of NCT05720325 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is studying how , a newer asthma medication, helps people whose asthma is triggered by house dust mites. Researchers will expose you to dust mites in a controlled chamber to see how your body responds, and then give you either the medication or a placebo for 18 weeks while monitoring your symptoms during similar exposures.
Many people with asthma struggle with dust mite allergies, but doctors don't fully understand why some people respond better to treatment than others. This trial will help researchers figure out which patients benefit most from this medication and how it actually works to reduce symptoms.
You will start by visiting a special aeroallergen chamber where you'll be exposed to dust mites so researchers can understand how your body reacts to them. Based on your response, you'll then be randomly assigned to receive either the medication or a placebo for 18 weeks, with return visits to the chamber during this period to monitor how well the treatment is working and track any changes in your asthma symptoms.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
The University of Texas Health Science Center at San Antonio
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID), Regeneron Pharmaceuticals
Enrollment target
~88 participants
Started
March 2023
Primary completion
November 2026
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in June 2026.